← Back to patent-cliff list
ZD-526
Tier C — Watch / tradeZD-526
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Alzheimer's disease, Mild cognitive impairment
Regional status
US
-
EU
-
China
Phase II
2026-01-13
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ZD-526?
Approved indications include: Alzheimer's disease, Mild cognitive impairment.
When does the ZD-526 patent expire?
No public expiry year is available for ZD-526 yet; this page updates once verified.
How do I get a quote for ZD-526 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29